Literature DB >> 26883334

Risk Stratification in Multiple Myeloma.

Melissa Gaik-Ming Ooi1, Sanjay de Mel2, Wee Joo Chng2.   

Abstract

There are many prognostic variables in multiple myeloma and the difficulty is in deciding which is truly significant. The widely used International Staging System (ISS) does not incorporate genetics, age, and other important variables in its risk stratification. Although it has its own limitations, the recently published Revised International Staging System (R-ISS) that was built upon the framework of ISS, is a more comprehensive and predictive tool for multiple myeloma patients and should be henceforth utilised. We will review the current prognostic variables and their significance in this paper.

Entities:  

Keywords:  Chromosomal Abnormalities; International Staging System; Multiple Myeloma; Risk

Mesh:

Year:  2016        PMID: 26883334     DOI: 10.1007/s11899-016-0307-4

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  113 in total

1.  Hypodiploidy is a major prognostic factor in multiple myeloma.

Authors:  N V Smadja; C Bastard; C Brigaudeau; D Leroux; C Fruchart
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

2.  Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.

Authors:  Jennifer S Carew; Steffan T Nawrocki; Yelena V Krupnik; Kenneth Dunner; David J McConkey; Michael J Keating; Peng Huang
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

3.  Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

Authors:  J P Sharman; J Chmielecki; D Morosini; G A Palmer; J S Ross; P J Stephens; J Stafl; V A Miller; S M Ali
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-06-11

4.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

Authors:  Wee Joo Chng; Scott A Van Wier; Gregory J Ahmann; Jerry M Winkler; Syed M Jalal; Peter Leif Bergsagel; Marta Chesi; Mike C Trendle; Martin M Oken; Emily Blood; Kim Henderson; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

5.  Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.

Authors:  Marco Ladetto; Gloria Pagliano; Simone Ferrero; Federica Cavallo; Daniela Drandi; Loredana Santo; Claudia Crippa; Luca De Rosa; Patrizia Pregno; Mariella Grasso; Anna Marina Liberati; Tommaso Caravita; Francesco Pisani; Tommasina Guglielmelli; Vincenzo Callea; Pellegrino Musto; Clotilde Cangialosi; Roberto Passera; Mario Boccadoro; Antonio Palumbo
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

Review 6.  Vulnerability in the elderly: frailty.

Authors:  Joris P J Slaets
Journal:  Med Clin North Am       Date:  2006-07       Impact factor: 5.456

7.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

8.  Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

Authors:  Sara Bringhen; Maria Victoria Mateos; Sonja Zweegman; Alessandra Larocca; Antonietta Pia Falcone; Albert Oriol; Davide Rossi; Maide Cavalli; Pierre Wijermans; Roberto Ria; Massimo Offidani; Juan Jose Lahuerta; Anna Marina Liberati; Roberto Mina; Vincenzo Callea; Martijn Schaafsma; Chiara Cerrato; Roberto Marasca; Luca Franceschini; Andrea Evangelista; Ana-Isabel Teruel; Bronno van der Holt; Vittorio Montefusco; Giovannino Ciccone; Mario Boccadoro; Jesus San Miguel; Pieter Sonneveld; Antonio Palumbo
Journal:  Haematologica       Date:  2013-02-26       Impact factor: 9.941

9.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Authors:  Jonathan J Keats; Tony Reiman; Christopher A Maxwell; Brian J Taylor; Loree M Larratt; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

10.  Fractal characteristics of May-Grünwald-Giemsa stained chromatin are independent prognostic factors for survival in multiple myeloma.

Authors:  Daniela P Ferro; Monica A Falconi; Randall L Adam; Manoela M Ortega; Carmen P Lima; Carmino A de Souza; Irene Lorand-Metze; Konradin Metze
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

View more
  4 in total

1.  DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.

Authors:  Scott R Goldsmith; Mark A Fiala; Brandon Wang; Mark A Schroeder; Tanya M Wildes; Armin Ghobadi; Keith Stockerl-Goldstein; Ravi Vij
Journal:  Ann Hematol       Date:  2020-03-04       Impact factor: 3.673

2.  Effects of survivin on FVADT chemotherapy for refractory multiple myeloma.

Authors:  Hua Yang; Xingjun Du; Yuren Xi
Journal:  Exp Ther Med       Date:  2016-05-26       Impact factor: 2.447

3.  Super-Enhancer Associated Five-Gene Risk Score Model Predicts Overall Survival in Multiple Myeloma Patients.

Authors:  Tingting Qi; Jian Qu; Chao Tu; Qiong Lu; Guohua Li; Jiaojiao Wang; Qiang Qu
Journal:  Front Cell Dev Biol       Date:  2020-12-03

4.  Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation

Authors:  Rafiye Çiftçiler; Hakan Göker; Haluk Demiroğlu; İbrahim Celalettin Haznedaroğlu; Nilgün Sayınalp; Salih Aksu; Osman Özcebe; Yahya Büyükaşık
Journal:  Turk J Haematol       Date:  2020-06-16       Impact factor: 1.831

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.